Rare diseases, important grant support for IRB Bellinzona

Dr. Maurizio Molinari, Group Leader at IRB
Dr. Maurizio Molinari, Group Leader at IRB

Institutional Communication Service

24 July 2019

The consortium formed by the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera italiana), Gain Therapeutics SA, a Swiss biotechnology company, and Neuro-Sys SAS in Gardanne (France), have announced it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. For IRB, the grant is assisgned to the research group led by Dr. Maurizio Molinari for his work in the field of rare diseases.

"The transnational collaboration with Gain Therapeutics and Neuro-Sys will hopefully offer the opportunity to translate into the clinics, the research activity performed at the IRB and aiming at understanding how perturbations in protein folding may cause severe diseases”, commented Dr. Maurizio Molinari, Group leader at the IRB, and Adjunct Professor at the École Polytechnique Fédérale de Lausanne (EPFL).


Full details at: www.irb.usi.ch/gain-therapeutics-sa-announces-award-notification-eu14m-grant-support-eurostars-2-together-institute